Why We Hold What We Hold

Deep Dives

Reviewed
4 of 23
Updated Aug 1, 2026 · 3:25 PM
Undocumented conviction · 12 positions · 19.7% of the book
BSOL4.0% of bookLOW evidence · conviction 6/10 — conviction without a documented case
CLPT3.5% of bookLOW evidence · conviction 6/10 — conviction without a documented case
ORR2.9% of bookLOW evidence · conviction 5/10
FCG2.4% of bookLOW evidence · conviction 5/10
TWST1.8% of bookLOW evidence · conviction 5/10
TXG1.0% of bookLOW evidence · conviction 5/10
TEM1.0% of bookLOW evidence · conviction 5/10
RGEN0.9% of bookLOW evidence · conviction 5/10
SPCX0.7% of bookLOW evidence · conviction 5/10
SANA0.5% of bookLOW evidence · conviction 3/10
PRME0.5% of bookLOW evidence · conviction 3/10
ABCL0.5% of bookLOW evidence · conviction 3/10
Positions with a LOW evidence grade hold capital without a completed valuation or trend case. Each clears only when its deep dive documents a fair-value model or a defensible trend thesis for the stated horizon. This list is supposed to reach zero.
BITB Bitcoin
ANCHOR · 21.9% · $662,122 · horizon: full cycle, into 2027-28 · evidence MED · conviction 8/10 · REVIEWED
Thesis Thesis 7: Bitcoin four-year-cycle accumulation. Institutional structure (spot ETFs, record LTH holdings) plus deep-value model reads (composite below -1, ~0.5x fair value) argue the 2026 bear is a bottoming process, not a secular top. BITB is the clean spot vehicle without leverage.
Edge Patience plus model-gated DCA at levels most flows are selling; no leverage, no credit risk.
What kills it A structural adoption break (ETF regime reversal, US hostility), or price action invalidating the cycle frame (no bull by late 2027). Adds are trigger-gated, never narrative-gated.
Verdict KEEP at current size; no adds while governor RED; digital cluster <=35%
Valuation case
Method Power-law fair-value model (the book's own btc_model)
Fair value Model fair value ~$117K vs ~$60K spot = 0.51x; composite -1.1 (deep value zone)
Variant view Market prices cycle death; the model + LTH/whale accumulation data say accumulation zone. Evidence is model-based on n=3 prior cycles - inherently MED, never HIGH.
Full deep dive · 2026-07-28

BITB — Bitwise Bitcoin ETF · Deep Dive

Position: 19,400 sh ≈ $683K · 22.6% of NAV (largest position) · Sleeve: Bitcoin · Role: ANCHOR

Written: 2026-07-28 · Next review: 2027-01-31 or on any falsifier event

1. Thesis

Bitcoin is in the bear phase of its fourth four-year cycle, and this bear is a bottoming

process, not a secular top. The structural case: spot-ETF plumbing survived its first full

drawdown intact; long-term holders own a record ~16.1M BTC; the largest single whale

accumulation spike on record printed near $59K; and the book's own power-law model reads

deep value (composite ≈ −1.1, price ≈ 0.5x the ~$117K fair-value line, Mayer 0.79,

Fear & Greed in the teens). The bet is that the 2026 lows are within the accumulation zone

of a cycle whose expansion phase runs 2027–28.

2. Vehicle choice

BITB over the alternatives, deliberately: spot exposure at a 0.20% fee with zero leverage,

zero credit risk, zero key-man risk. MSTR is a leveraged wrapper (owned indirectly via STRC

on the income side instead — the two legs are intentionally separated); futures ETFs bleed

roll; self-custody adds operational risk the size does not justify. BITB is exempt from the

R2 single-name cap by design because it is the asset, not a company.

3. Edge and base rates

The claimed edge is behavioral and structural, not informational: willingness to hold and

accumulate through a −50%+ drawdown that flows-driven sellers (ETF outflows $200–500M/day

at the worst; IBIT sold ~$5B over 60 days) cannot. Base rates that frame the bet:

  • Every prior cycle put its bear-market low 12–18 months after the peak; this bear is

~9–10 months old (peak Sep–Oct 2025). Cowen's midterm-year frame: bears run ~50–60

weeks, modal low around October 2026.

  • Prior cycle bears bottomed at −77% and −84% from peak; this one has run ~−55% from

~$126K to the $57–60K zone — consistent with the milder-bear/institutional-era view,

but the low-$30Ks tail (Wadsworth) is not dead and must stay priced.

  • Post-halving cycle expansion has followed every accumulation zone so far (n=3 — a

small sample; that smallness is the honest core risk of the whole thesis).

4. Key numbers (as written)

BTC ~$59–66K range for six weeks. Model: fair value $117K, composite −1.07 to −1.29

(lump-sum trigger −1.3), 200DMA ~$77K (0.85x), Feb low $62,791 broken in June (bearish

structure), double-bottom attempt at $59–60K. 89% of supply unmoved in 3 months

(2nd-highest illiquidity ever). Position cost basis ≈ $33.69/sh vs $35.2 last mark:

roughly flat on a position built across the cycle.

5. Falsifiers and pre-committed actions

  • Cycle failure: no new all-time high by end-2027 → the four-year frame is broken;

cut the anchor to core size (≤15%) regardless of narrative.

  • Structural break: US regulatory hostility to spot ETFs, or a sustained ETF outflow

regime that persists even through rate cuts → thesis void, exit to target.

  • Model break: power-law fair value revised materially down by the model's own data.
  • Adds: ONLY via the pre-committed triggers (btc_repair weekly-close, btc_lumpsum at

composite ≤ −1.3). No narrative adds. Cluster cap: digital assets ≤35% NAV binds the

total (BITB+BSOL+COIN currently ~27.7%; STRC counted separately as income).

  • Governor override: while the drawdown governor is at rung 3, no adds at all, even

if a trigger fires — capital preservation outranks accumulation.

6. Horizon

Full cycle: hold through 2027–28 expansion. This is explicitly not a trade; the SRS/

monthly-chart discipline applies to adds, not to the core.

7. Verdict

KEEP at current size. The position passes: it is the book's largest conviction with a

documented model edge, statement-verified sizing inside the cluster cap, pre-committed

falsifiers, and a defined horizon. What it does NOT justify: adding while the governor is

RED, or letting the digital-assets cluster creep past 35% via BSOL/COIN drift. The single

largest intellectual risk is sample size — three prior cycles is weak evidence, and the

whole anchor rests on it. Size (22.6%) is aggressive but consistent with the ratified

allocation target; revisit at the January 2027 review or a falsifier, whichever first.

TSLA Tesla
CORE · 15.4% · $466,815 · horizon: 2-3 years (robotaxi ramp) · evidence HIGH · conviction 4/10 · REVIEWED
Thesis Robotaxi/FSD commercialization is inflecting (statewide Texas launch, 150+ cybercabs/day run-rate) with energy storage as a second engine. The market still prices it mostly as a carmaker.
Edge Conviction through drawdowns on the autonomy S-curve; SRS discipline for entries.
What kills it Against position: EA26002 escalates; teleoperator dependency into 2027; Cybercab <50K/yr by mid-27; FSD growth <25%. Against our bear model: driver-out fleet >1,000 across 5+ metros; robotaxi revenue >$500M/yr; FSD subs >2.5M by mid-27.
Verdict TRIM to 10% (R2): our model says price embeds ~85% of bull-case autonomy; FSD growth is the real kernel - keep 10%, cut the cap breach.
Our valuation model · scenario_sotp · computed 2026-08-01
Fair value $126 vs price $311 (-60%)
Scenario / componentProbValue/sh
Auto hardware (80B rev x 4% x 25x)$20
FSD software (FY28E) (3.3B rev x 65% x 35x)$19
Energy (FY27E) (15B rev x 8% x 28x)$9
bear: program stays niche/stalls (fleet ~42-59 cars now; teleoperators drive; EA26002 open)45%$5
base: Cybercab ramps 2027-30 to ~300-500k vehicles (125k/yr installed capacity), profitable ~203040%$76
bull: 1M+ global fleet + FSD licensing at software margins15%$304
Read Core business worth ~$48/sh; everything above that is the autonomy option, probability-weighted at $78/sh.
Assumptions EVIDENCE-REVISED 2026-07-28 (108-agent verified research, see deep_dives/TSLA.md). Auto: Q2-26 rev +26%, deliveries 480k (+25%) but GAAP op margin 1.4%; TTM co-wide net margin 3.7% -> auto 4% normalized (cyclical price war, volume growth real). FSD is the strongest verified positive: 1.48M subs +56% YoY, >55% NA attach -> modeled as FY28 3.2M subs x ~$85/mo at software margins. Energy: TTM 12.8B +13% rev (NOT 16B +30%), GM 20.4% on warranty charges; GWh +41% with price deflation -> FY27 15B x 8%. Robotaxi: registered fleet 42-59 vehicles vs Waymo ~3,000-3,600 doing 500k+ paid rides/wk; ~2.5M cumulative paid miles; teleoperators still drive (<10mph authority, 3 collision reports); Austin availability ~19% of hours (Feb-26); Cybercab capacity 125k/yr = 1M fleet mechanically 5+ yrs out; Waymo at 100x scale books only ~$100-130M revenue/QUARTER -> probability mass shifted bear-ward (45/40/15 from 35/45/20) and base PV cut 600->300B on timeline discounting. CHALLENGE MODEL ADDED 2026-07-28: Cern Basher (95-agent verified research). His core-only bear anchor $132-234/sh brackets our $126; his full-model upside comes from 10M robotaxis by 2030 and Optimus at P/E 100, with no published probabilities and no verified 2026 revision after actual fleet data printed.
Cross-check Street consensus target $435 — informational only, never an input.
Challenge models · external, labeled, never inputs
ModelFair valueKey inputs
Cern Basher — bear anchor (core business only) · Aug 25, 2025 model (latest full version found; no verified 2026 revision)$132–$234/shCore-only floor from his Sum-of-the-Parts: deliveries 1.7M->7.5M by 2030, 20% net auto margin, energy 50->3,000 GWh by 2035; robotaxi + Optimus EXCLUDED. His verbal range (Mar-25): fair value 'probably between 200 and a thousand'. All tables footnoted 'Illustration, not a prediction'.
Disputed Deliveries: his 7.5M by 2030 needs ~41%/yr compounding; Tesla's verified 2026 run-rate is 1.9M growing 25% - the same growth rate sustained gives ~3.7M by 2030, half his path.
Disputed Auto net margin: his 20% vs verified TTM company-wide 3.7% (peak in company history ~15%, 2022). No evidence supports 20% while volume is bought with price cuts.
Disputed Robotaxi scale: his 10M-vehicle fleet by 2030 vs verified reality: ~42-59 registered vehicles, teleoperators driving, and 125K/yr Cybercab installed capacity - 10M by 2030 requires ~80x current capacity.
Disputed FSD, cuts AGAINST our model too: his own late-Jul 2026 chart shows ~666K paying subscribers / ~$800M ARR (Tesla's 1.48M 'active subscriptions' metric includes past upfront purchases). Our FY28E $3.3B FSD revenue input is likely TOO HIGH, not too low - flagged for the next assumptions revision.
Disputed Where we AGREE: strip the unproven robotaxi/Optimus options to their floor and his core value ($132-$234) brackets our $126 fair value. The disagreement is entirely about how much to pay TODAY for options whose current scale is ~50 cars.
Full deep dive · 2026-07-28

TSLA — Tesla · Deep Dive

Position: 1,500 sh ≈ $464K · 15.3% of NAV (2nd largest; ABOVE the 12% hard cap) · Sleeve: AI · Role: CORE

Written: 2026-07-28, on a 108-agent verified evidence pack (25 sources fetched, 122 claims extracted,

25 adversarially verified 3-vote each: 24 confirmed, 1 refuted) · Next review: on Q3-26 earnings or any falsifier

1. Thesis (as held)

Robotaxi/FSD commercialization inflecting, energy storage as second engine, market pricing it as a carmaker.

The deep dive's job: test that against primary evidence and price the pieces ourselves.

2. What the verified evidence says

The good (primary-source confirmed):

  • Q2-26 revenue $28.2B, +26% y/y; record 480,126 deliveries (+25%, ~1.9M annualized). Demand is not the problem. [Tesla IR Q2-26 deck + deliveries release]
  • FSD: 1.48M active subscriptions, +56% y/y, >55% North America attach on new deliveries, five new EU

country approvals. This is the strongest single piece of bull evidence — a real, growing, high-margin

software stream. [Tesla IR Q2-26 deck]

  • Energy deployments 13.5 GWh in Q2, +41% y/y. Volume growth intact. [Tesla IR]
  • Cybercab production started at Giga Texas, >125K/yr installed capacity. The dedicated-vehicle path exists. [Tesla IR]

The bad (primary-source confirmed):

  • Margins collapsed: Q2-26 GAAP operating margin 1.4% (-57% y/y op income); TTM net margin ~3.7%

company-wide ($3.8B NI on $103.6B revenue). The volume came from price cuts. [Tesla IR; arithmetic verified]

  • Energy REVENUE grows only +13% (TTM $12.8B) despite +41% GWh — $/kWh deflation eats the volume; gross

margin compressed to ~20.4% by vendor-cell warranty charges. [Tesla IR]

  • Robotaxi scale is trivial: ~2.5M cumulative paid miles ever (IR deck chart). Texas DMV registry: 42

authorized Tesla vehicles vs 577 Waymo (May-26); ~16-20 active unsupervised in Austin, shrinking since

April. Bloomberg counts ~59 registered total. [TX DMV via multiple outlets; crowdsourced trackers]

  • Remote teleoperators still DRIVE the vehicles (sub-10mph authority per Tesla's statement to lawmakers);

three NHTSA-filed collisions occurred while a teleoperator was driving. Austin service availability was

~19% of operating hours as of Feb-26. [NHTSA SGO filings, unredacted May-26; Robotaxi Tracker]

  • Federal overhang: NHTSA Engineering Analysis EA26002 (Mar-26) covers ~3.2M FSD vehicles on camera-only

degraded-visibility performance. Open as of July. [NHTSA ODI resume, primary]

  • The benchmark that reprices the dream: Waymo runs ~3,000-3,600 driverless vehicles doing 500K+ paid

rides/week — roughly 100x Tesla's robotaxi scale — and books only ~$100-130M revenue per QUARTER.

Even the category leader at scale is a sub-$1B/yr revenue business today. [NHTSA recall scope; Waymo

announcements; FutureSearch estimates — the unit-economics numbers are estimates, flagged as such]

Refuted in verification (0-3): the claim that the service ran in only four cities with a 10-14 sq-mi

Miami zone — the IR deck's seven-metro list is the anchor.

Evidence gaps (honest): no verified robotaxi unit economics for anyone (Tesla's cost/mile, pricing,

utilization; Waymo's profitability); no verified sell-side implied-robotaxi decomposition; China FSD and

Chinese competitor scale unverified. The $40K-gross-profit-per-vehicle-year input remains judgment.

3. Our model (evidence-revised 2026-07-28)

Sum of the parts, 3.95B fully diluted shares:

| Component | Inputs | Value/sh |

|---|---|---|

| Auto hardware | 80B rev × 4% normalized margin × 25x | ~$20 |

| FSD software | FY28E 3.2M subs → 3.3B rev × 65% × 35x | ~$19 |

| Energy | FY27E 15B rev × 8% × 28x | ~$9 |

| Robotaxi bear (45%) | program stays niche; PV $20B | $5 × 0.45 |

| Robotaxi base (40%) | Cybercab ramps to 300-500K vehicles by ~2030-32; PV $300B | $76 × 0.40 |

| Robotaxi bull (15%) | 1M+ global fleet + licensing; PV $1.2T | $304 × 0.15 |

| Fair value | | ~$126 |

vs price ~$306 → our model says -59%. Street consensus $435 (cross-check only, never an input).

Probability sensitivity (the whole argument lives here):

| Probability set (bear/base/bull) | Option value/sh | Fair value |

|---|---|---|

| Evidence-weighted (45/40/15) — ours | $78 | ~$126 |

| v0 seed (35/45/20) | $97 | ~$145 |

| Bull-tilted (25/45/30) | $127 | ~$175 |

| Required to justify $306 | ~$258 | $306 |

Market-implied expectations: at $306 the market pays ~$1.02T for the autonomy option (price minus

core). That is ~85% of our BULL-case PV — i.e., the market prices near-certain success of a program that

today has ~50 running cars, teleoperators doing the driving, and a category leader 100x its size booking

under $1B/yr of revenue. For OUR model to be wrong and the market right, Cybercab must ramp near its full

125K/yr capacity immediately AND unit economics must exceed anything any operator has demonstrated.

4. Falsifiers — both directions, pre-committed

Against the position (act on these): EA26002 escalates to recall of camera-only FSD; teleoperator

dependency persists into 2027; Cybercab run-rate <50K/yr by mid-2027; FSD subscription growth <25% y/y.

Against our bearish model (raise the PVs if these print): driver-out fleet >1,000 vehicles across 5+

metros; disclosed robotaxi revenue run-rate >$500M/yr; supervision-free miles-per-intervention data at

human-parity; FSD subs >2.5M by mid-2027 (raises both FSD leg and base-case probability).

5. Horizon

The autonomy option resolves substantially by 2028 (Cybercab ramp + EA26002 + driver-out data). The

position is NOT a hold-forever compounder at this price; it is an option trade where we now have evidence

the option is expensively priced.

6. Verdict

TRIM to the 10% target (R2 rule), keep the remainder. The thesis kernel is real — FSD software growth

is the best-verified bull fact in the book, and the Cybercab line exists. But our own model, built on

primary sources, says the current price embeds ~85% of the bull case while the operational evidence sits

closest to the bear case. Holding 15.3% (above the hard cap, 12 days in breach) means betting overweight

AND against our own model AND against the governor's rung-3 de-gross order. Trimming ~$160K to 10%

satisfies the R2 breach, funds the cash floor the governor demands, and keeps full upside participation

on two-thirds of the position if the FSD evidence keeps compounding. Conviction: 4/10 at this price

(would be 7/10 at ~$150). Evidence grade: HIGH (verified pack on file).

7. Challenge model: Cern Basher (added 2026-07-28, Ian's request)

Basher joined the ingestion roster as the named TSLA challenge model. A 95-agent verified research pass

reconstructed his published record (X posts date-verified via tweet-ID decoding; tables OCR'd):

  • His most recent full model (Aug 25, 2025 Sum-of-the-Parts): deliveries 1.7M → 7.5M by 2030 at 20%

net margins (auto worth up to $900B); energy to 3,000 GWh by 2035 (up to $1.35T); robotaxi ~10M

vehicles by 2030 at $90/day/vehicle; Optimus 1.55M bots by 2030 at $135/day. Full stack: $2,452–$5,425/sh.

  • His own bear anchors: core-business-only floor $132–$234/sh; halved-volume auto case ~$450B;

spoken range (Mar-25) "probably between 200 and a thousand." Every table footnoted

"Illustration, not a prediction," with no published probability weights.

  • No verified 2026 model revision after actual robotaxi fleet data, Q2-26 earnings, or the stock's

2026 decline. His only verified 2026 output is a July FSD chart: ~666K paying subscribers, ~$800M ARR.

Resolution of the input disputes (evidence-settled): his 7.5M-by-2030 deliveries need ~41%/yr

compounding vs the verified 25%; his 20% auto net margin has never been achieved (verified TTM 3.7%,

historic peak ~15%); his 10M-robotaxi-2030 fleet requires ~80x the Cybercab line's installed capacity.

None of these inputs move our model, because none carry evidence. One of his data points DOES move us,

in the bearish direction: his ~$800M FSD ARR chart implies our FY28E $3.3B FSD revenue leg is likely

too high — flagged for the next assumptions revision.

The verdict this produces: adopting "Basher's bear case as our base case" — the literal request —

sets fair value at $132–$234, bracketing our $126 and sitting 24–57% BELOW the market price. His

divergence from us is not about the business that exists; it is about assigning near-certain success

to a 10M-vehicle robotaxi fleet and an Optimus empire, without probabilities. Our model prices those

as options with evidence-weighted probabilities. The TRIM-to-10% verdict stands, reinforced.

STRC STRC
CORE · 13.0% · $393,624 · horizon: income leg, indefinite while covered · evidence MED · conviction 7/10 · DRAFT
Thesis Strategy's 12% preferred. Dividend reserve more than doubled to ~$2.55B (~17-18 months coverage, board-approved floor), first-ever buyback authorizations, ~5-6x over-collateralized by the BTC stack. Drawdowns have been flows-driven, not credit-driven.
Edge Structurally senior to the equity with self-healing yield mechanics (price down = yield up = buyers return toward par).
What kills it A dividend cut, reserve drawdown without replenishment, or BTC falling below the ~8%/yr appreciation path that covers the dividend long-term.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
QURE UniQure
CORE · 5.4% · $163,612 · horizon: to BLA decision + launch, 2026-2028 · evidence MED · conviction 7/10 · DRAFT
Thesis AMT-130 for Huntington's: 3-year data accepted as the BLA primary basis (75% cUHDRS slowing), filing 3Q26. Rare-disease structural base rate 17% with a NAMED reason to sit above it - that is what passes the EV gate and justifies anchor sizing.
Edge Base-rate honesty plus pre-committed add triggers (clean Type-B, 4-yr data), never article momentum.
What kills it CRL or clinical hold on manufacturing/safety, negative 4-year data, or the FDA reversing its acceptance stance.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
CEF 60/40 Gold & Silver
CORE · 5.3% · $160,040 · horizon: multi-year (fiscal regime) · evidence MED · conviction 7/10 · DRAFT
Thesis Thesis 5: debt debasement. ~$30T gross Treasury issuance, interest expense compounding ~12%/yr vs ~1.6% nominal GDP, every curve point above the average debt cost. Gold plus silver in one discounted closed-end vehicle.
Edge Hard-asset ballast that has actually worked (gold +64% in 2025); the CEF discount adds a second return source.
What kills it Credible fiscal consolidation or a sustained positive real-rate regime with falling issuance.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
BSOL Solana
CORE · 4.0% · $119,640 · horizon: 1-3 years · evidence LOW · conviction 6/10 · DRAFT
Thesis Solana staking exposure. SOL is the leading high-throughput stablecoin/payments rail (tokenized stocks +3,300% y/y, mostly on Solana) and the most credible settlement layer for agentic-payment volume if that thesis matures. Staking yield compounds while waiting.
Edge Yield-bearing exposure to the strongest non-BTC usage story.
What kills it Sustained loss of stablecoin/payments share to Base or others; a second credible outage era.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
CLPT ClearpointNeuro
CORE · 3.5% · $104,580 · horizon: rides QURE catalyst plus platform adoption · evidence LOW · conviction 6/10 · DRAFT
Thesis ClearPoint is the delivery-platform partner for AMT-130 (and other MRI-guided neuro therapies): the picks-and-shovels expression of the gene-therapy-delivery bottleneck, without single-asset binary risk.
Edge Every approved neuro gene therapy needs delivery; CLPT monetizes procedures regardless of whose drug wins.
What kills it AMT-130 failure (near-term correlation is high), or a rival delivery standard displacing the platform.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
SGOV T-bills
UTILITY · 3.3% · $100,716 · horizon: rolling · evidence HIGH · conviction 9/10 · DRAFT
Thesis T-bill parking for cash above the working floor; 4%+ yield instead of idle-cash drag (R7 rule).
Edge None claimed; this is cash management.
What kills it n/a
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
ORR ORR Long/Short ETF
UTILITY · 2.9% · $87,278 · horizon: rolling · evidence LOW · conviction 5/10 · DRAFT
Thesis Long/short ETF as a beta damper: keeps equity exposure while cutting net beta in a book that runs hot (realized beta ~3x vs SPY).
Edge None claimed; risk architecture.
What kills it Sustained negative alpha vs simply holding cash plus index (check in sleeve attribution).
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
FCG Natural Gas ETF
SATELLITE · 2.4% · $73,375 · horizon: 1-2 years · evidence LOW · conviction 5/10 · DRAFT
Thesis Natural gas equities: gas is the marginal fuel for AI-driven power growth and LNG export capacity keeps ramping. Complements VST (generator) with upstream exposure.
Edge Same power-demand thesis, different node of the value chain.
What kills it Sustained sub-$3 gas from associated-gas oversupply; LNG project delays.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
PSCE Small Cap Energy ETF
SATELLITE · 2.4% · $72,082 · horizon: 12-18 months · evidence HIGH · conviction 3/10 · REVIEWED
Thesis Small-cap E&P basket: cheap on cash flow, levered to the oil geopolitical tail (thesis 3 residual: war-resumption risk after the Iran MOU) without single-well risk.
Edge Asymmetry: soft floor from valuation, fat tail from Hormuz/Israel re-escalation.
What kills it Thesis 3 conviction is 38% with WTI well below the $89 floor; if the tail closes (durable peace plus glut), this is dead money - exit per trigger board.
Verdict SWAP OUT into BNO dollar-for-dollar: our 895-day study shows PSCE captures only 0.48 of Brent spikes - wrong vehicle for the thesis-3 tail it was bought to express.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
Full deep dive · 2026-07-29

PSCE — Invesco S&P SmallCap Energy ETF · Deep Dive

Position: ~$70K · 2.3% of NAV · Sleeve: Energy · Role: SATELLITE

Written: 2026-07-29 · Next review: n/a if swap executes

1. Thesis (as held) vs what the vehicle actually does

The thesis card said: "small-cap E&P basket, cheap on cash flow, levered to the oil geopolitical tail

without single-well risk." The deep dive tested the second claim with our own 895-day study and it is

false in the way that matters: PSCE's spike-day capture of Brent moves >+2% is 0.48 — the tail

exposure is half of what the thesis assumed. On 2026-07-28, with Brent +3.8% on the repelled Iran

attack, PSCE printed +1.4% while XOP did +3.0% and BNO ~+3.5%. The vehicle is fine; it is simply not

the instrument for the thesis it was bought to express.

2. What PSCE actually is

Small-cap S&P 600 energy: junior E&Ps plus oilfield services and equipment. Its returns carry small-cap

equity beta (drag on red tape days), heavy producer hedging (mutes near-term price capture), and a

services component with no direct crude linkage. It IS a reasonable multi-year value vehicle: +35.4%

trailing 12 months, and it beat spot Brent over that window. But the book holds it against a dated

spike thesis (thesis 3, 38% conviction, post-midterm window), and for that job it is mis-specified.

3. Verdict

SWAP OUT into BNO, dollar-for-dollar (see deep_dives/BNO.md for the receiving thesis, capture

table, EV gate, and pre-committed exits). No net risk change; governor respected. If Ian would rather

own the VALUE thesis than the SPIKE thesis, the correct alternative is keeping energy-equity exposure

via XOP (broader, purer E&P) — but then the position should be re-labeled as a valuation bet with a

multi-year horizon and removed from the thesis-3 expression list, because it cannot do that job.

Evidence grade: HIGH (own capture study). Status: REVIEWED.

TWST Twist Biosciences
SATELLITE · 1.8% · $54,930 · horizon: 2-3 years · evidence LOW · conviction 5/10 · DRAFT
Thesis DNA synthesis platform leader: tools/picks-and-shovels on synthetic biology and AI-designed proteins, monetizing research volume regardless of which therapeutic wins.
Edge Platform economics vs binary clinical risk.
What kills it Price competition eroding gross margin; cash burn without operating leverage.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
LLY Eli Lilly
CORE · 1.1% · $34,455 · horizon: 3-5 years · evidence LOW · conviction 6/10 · DRAFT
Thesis GLP-1 franchise dominance (tirzepatide plus the oral pipeline) with the deepest obesity/metabolic moat in pharma. The quality-compounder ballast of the biotech sleeve.
Edge Low-beta (0.5) anchor that lets the sleeve hold higher-risk names elsewhere.
What kills it Oral GLP-1 competitive miss, pricing/policy shock (IRA expansion), pipeline gap after 2030.
Our valuation model · dcf · computed 2026-08-01
Fair value $717 vs price $1,148 (-38%)
Scenario / componentProbValue/sh
PV of 10y FCF (20% x5y fading to 8%)$229
Terminal value (3% growth, 8% WACC)$520
Less net debt$-32
Read Two-stage DCF at 8% WACC; terminal 3%.
Assumptions FY25: revenue 65.2B (+45%), NI 20.6B, but FCF only 9.0B because capex runs ~7.8B/yr on manufacturing buildout. FCF start normalized to 14B (capex plateaus), 20% growth x5y fading to 8% (competition + patent horizon), 8% WACC. NOTE: at ~56x trailing earnings the market prices growth well beyond this conservative case - if OUR model is right the stock is rich; the deep dive must decide whether to raise the growth assumptions with evidence or respect the model and keep the position small.
Cross-check Street consensus target $1,315 — informational only, never an input.
TXG 10x Genomics
SATELLITE · 1.0% · $30,726 · horizon: 2-3 years · evidence LOW · conviction 5/10 · DRAFT
Thesis Single-cell/spatial genomics tools leader trading near cycle lows on funding-driven revenue weakness; recovery play on research budgets plus new platform cycles.
Edge Buying the tools leader in a downcycle.
What kills it Structural (not cyclical) demand loss; failed platform transitions; continued cash burn.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
TEM Tempus
SATELLITE · 1.0% · $30,709 · horizon: 2-3 years · evidence LOW · conviction 5/10 · DRAFT
Thesis AI diagnostics/clinical-data platform: the data-moat play on AI-in-medicine, monetizing sequencing plus records at scale.
Edge Rare pure-play on clinical AI data network effects.
What kills it Reimbursement pressure, data-rights litigation, or unit economics failing to improve with scale.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
RGEN Repligen
SATELLITE · 0.9% · $28,202 · horizon: 2-3 years · evidence LOW · conviction 5/10 · DRAFT
Thesis Bioprocessing picks-and-shovels: consumables for biologics/gene-therapy manufacturing, recovering from the post-COVID destocking cycle.
Edge Volume-based, approval-agnostic biotech exposure.
What kills it Prolonged destocking, share loss to integrated suppliers.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
COIN Coinbase
SATELLITE · 0.8% · $25,596 · horizon: 2-4 years · evidence LOW · conviction 6/10 · DRAFT
Thesis Crypto infrastructure equity: Base L2, x402 agentic-payments protocol authorship, custody and on/off-ramp economics. The cleanest equity capture of stablecoin/agentic settlement growth regardless of which token wins.
Edge Equity value capture where token value capture is weak.
What kills it Fee compression outrunning new revenue lines; regulatory reversal on staking/custody; x402-class volume failing to materialize by 2028.
Our valuation model · revenue_multiple_scenarios · computed 2026-08-01
Fair value $215 vs price $146 (+47%)
Scenario / componentProbValue/sh
bear: crypto winter extends, fee compression, rev 4B @ 5x30%$77
base: cycle turn 2027 + Base/custody growth, rev 7B @ 8x50%$215
bull: agentic-payments materialize on Base + bull market, rev 11B @ 10x20%$423
Read Probability-weighted revenue multiples across the cycle.
Assumptions Revenue is cyclical with crypto prices; the bull leg is the x402/Base agentic option discussed 2026-07-28 (probability deliberately only 20% - the CoinDesk volume data says demand is not there yet).
Cross-check Street consensus target $219 — informational only, never an input.
SPCX SpaceX
SATELLITE · 0.7% · $21,674 · horizon: through post-IPO lockups, 2026-27 · evidence LOW · conviction 5/10 · DRAFT
Thesis SpaceX exposure (fund wrapper): Starlink cash-flow inflection plus the launch monopoly, bought around the record IPO. Thesis 6 flags the supply wall (~$1.2T net issuance, lockups mid-July/Aug) so sizing stays modest.
Edge Access to the scarcest mega-asset; the discipline is the small size, not the story.
What kills it Priced >90x sales at IPO; a Starlink growth miss or lockup-driven supply break re-rates it hard. Exit discipline on the trigger board.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
SANA Sana Biotech
LOTTERY · 0.5% · $15,650 · horizon: catalyst-dependent · evidence LOW · conviction 3/10 · DRAFT
Thesis Hypoimmune cell-therapy platform (islet-cell T1D data). Part of the correlated basket (SANA/PRME/ABCL) counted as ONE bet under the concentration rule.
Edge Optionality only; sized as a lottery per EV-gate discipline.
What kills it Basket rule: a 0.5% ticket that halves with NO new catalyst is dead money - cut, do not average down.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
PRME Prime Medicine
LOTTERY · 0.5% · $14,600 · horizon: catalyst-dependent · evidence LOW · conviction 3/10 · DRAFT
Thesis Prime-editing platform optionality. Same basket as SANA/ABCL - one correlated bet on early-stage genetic medicine.
Edge Optionality only.
What kills it Basket rule as SANA; platform data failure or a financing wall.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
ABCL AbCellera
LOTTERY · 0.5% · $14,275 · horizon: catalyst-dependent · evidence LOW · conviction 3/10 · DRAFT
Thesis AI antibody-discovery platform with partnership economics. Third leg of the correlated basket.
Edge Optionality only.
What kills it Basket rule; partnership revenue failing to convert into clinical value.
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
VST
CORE · 0.0% · $0 · horizon: 2-4 years (power supercycle) · evidence LOW · conviction 6/10 · DRAFT
Thesis AI-power leg of the AI thesis: POWER, not FLOPs, is the binding constraint on AI buildout (tokens per megawatt). Vistra owns dispatchable generation (nuclear via Comanche Peak plus a large gas fleet) concentrated in ERCOT/Texas where data-center load growth is fastest, with 2.5-3 year transformer lead times protecting incumbents from new supply. Structural power-price upside plus data-center PPA optionality.
Edge Second-derivative AI exposure: gets paid on AI electricity demand whichever model lab wins; capacity already built while new entrants wait years in the interconnection queue.
What kills it AI capex bust cutting data-center load growth; ERCOT price-cap or windfall-profit intervention; efficiency gains (inference cost falling ~40x/yr) outrunning load growth so total MW demand flattens.
Our valuation model · ev_ebitda_scenarios · computed 2026-08-01
Fair value $155 vs price $148 (+5%)
Scenario / componentProbValue/sh
bear: power prices mean-revert, ERCOT intervention, EBITDA 5.0B @ 8x25%$72
base: data-center load growth holds, EBITDA 6.5B @ 11x50%$165
bull: PPA premium cycle + scarcity pricing, EBITDA 7.5B @ 12x25%$220
Read Probability-weighted EV/EBITDA across the power-price cycle; net debt 15.7B.
Assumptions FY25 EBITDA printed 5.3B (down from 7.2B FY24 on commodity swings); TTM EV/EBITDA 10.6x. The bet is forward EBITDA recovery on data-center PPAs with the multiple holding; bear case is the hedge roll-off plus a price-cap intervention. 2.5-3yr transformer lead times are why the multiple should hold.
Cross-check Street consensus target $222 — informational only, never an input.
BNO
SATELLITE · 0.0% · $0 · horizon: dated: through post-midterm window, hard review 2026-11-30 · evidence HIGH · conviction 5/10 · REVIEWED
Thesis Thesis 3 expression, corrected vehicle: Brent futures fund captures ~0.92 of Brent spike days vs PSCE's 0.48. Hormuz/war-resumption tail reprices seaborne Brent directly; WTI (USO) is buffered by Cushing/SPR in exactly the scenario that pays. Currently earning backwardation carry; contango flip is the holding cost to watch.
Edge Own capture study (895 days, 124 spike days) - instrument fidelity to the scenario, not a market view.
What kills it Thesis-3 conviction <25% -> exit. Brent <$70 -> exit. Contango >8%/yr for 2+ months without escalation -> exit/halve. Event fires (Brent >$110) -> trim at least half into the spike.
Verdict PRE-TRADE entry per rule: swap from PSCE same dollars (~2.3%), NO size increase (EV gate: 38% honest p vs 42% breakeven - clears only as a swap, not an add).
Valuation case
No fair-value model or documented trend case yet — produced by the deep dive.
Full deep dive · 2026-07-29

BNO — United States Brent Oil Fund · Deep Dive (pre-trade)

Proposed position: SWAP from PSCE, same dollars (~$70K, ~2.3% of NAV) · Sleeve: Energy · Role: SATELLITE (tail expression)

Written: 2026-07-29, pre-trade per the no-position-without-REVIEWED-thesis rule · Next review: thesis-3 conviction change, or 2026-11-30 (post-midterms), whichever first

1. Thesis being expressed

Thesis 3, the oil geopolitical tail: the Iran war resumes or Hormuz risk reprices (Pape framework: >50%

odds of renewed full war after the midterms; today's US-repelled Iran attack on a base is the tail firing).

This is a PRICE-SPIKE bet with a dated window, not an energy-equity valuation bet. The instrument must

capture a fast, front-month, seaborne-crude repricing.

2. Vehicle selection — the whole point of this dive

Our capture analysis, 124 Brent spike days (>+2%) since 2023, ~895 trading days:

| Vehicle | Spike-day capture | Beta to Brent | Corr | 12m return vs Brent +20.2% |

|---|---|---|---|---|

| USO (WTI futures) | 0.96 | 0.89 | 0.90 | +61.7% |

| BNO (Brent futures) | 0.92 | 0.86 | 0.92 | +55.7% |

| XOP (E&P equities) | 0.50 | 0.49 | 0.62 | +32.8% |

| PSCE (small-cap energy) | 0.48 | 0.48 | 0.55 | +35.4% |

| XLE (large-cap energy) | 0.37 | 0.36 | 0.59 | — |

Why BNO over USO despite USO's slightly higher historical capture: the scenario is a SEABORNE supply

shock. Roughly a fifth of global oil transits Hormuz; Brent is the waterborne global benchmark that

reprices it directly. WTI is the landlocked US benchmark buffered by Cushing storage, domestic supply,

and SPR politics — in Gulf-specific shocks the Brent-WTI spread widens, and USO's capture of that

specific scenario degrades exactly when the thesis pays. USO's 0.96 average is earned across ALL spike

days (many macro/demand-driven, where WTI keeps pace); BNO's capture is scenario-robust. We pay ~4pp of

average capture for fidelity to the actual bet. Statistically close; mechanically clear.

Why not stay in equities (XOP): half the capture (0.50), plus equity-market beta the governor is

trying to shed. XOP is the right vehicle for a multi-year energy VALUE thesis — that is not thesis 3.

3. Carry: currently a tailwind, watch for the flip

Both futures funds beat spot Brent by 35-41pp over the trailing 12 months — the war regime kept the

curve in backwardation, so rolling futures EARNED carry. Caveat, honestly: the June MOU + IEA glut

forecast can flip the curve to contango, turning carry into a bleed of roughly 5-10%/yr. That is the

cost of holding the tail. If the tail closes, the position exits anyway (falsifiers below), so the

worst-case is bounded bleed over a bounded window.

4. EV gate (run before sizing, per the RUNBOOK)

U (Hormuz/war event): Brent $110-130 (+30-50%) x 0.9 capture → +27-45%; use +0.35.

D (durable peace + glut): Brent to ~$70 (-20%) plus contango bleed → -0.25 over the horizon.

Breakeven p = 0.25/(0.35+0.25) = 0.42. Honest p = thesis-3 conviction = 0.38.

The gate says: below breakeven as a NEW bet — do not add. As a SWAP it still clears, because the

book already carries this thesis in a vehicle with HALF the upside capture and the same downside class:

swapping dollar-for-dollar strictly improves the payoff profile of risk already held. Sizing therefore

stays at PSCE's current ~2.3% — no increase, governor stays respected (swap, not add).

5. Falsifiers and pre-committed actions

  • Thesis-3 conviction drops below 25% (durable peace holds through the midterm window) → EXIT, no debate.
  • Brent closes below $70 → the glut regime won; EXIT.
  • Curve in contango steeper than ~8%/yr annualized for 2+ months with no escalation → the bleed

outruns the tail; EXIT or halve.

  • Event FIRES (Brent >$110): take the spike — trim at least half into strength per the spike-selling

discipline; this is a tail harvest, not a new trend thesis.

6. Horizon

Dated: through the post-midterm window (thesis 3's own framework), review 2026-11-30 hard stop.

This position is not a compounder; it has an expiry mindset.

7. Verdict

SWAP PSCE → BNO, same dollars (~2.3% NAV), no size increase. Today's tape was the proof: Brent

+3.8%, PSCE +1.4%. If the tail fires with the book positioned in PSCE, we get half-paid for full risk.

Trade is Ian's to execute; this entry satisfies the pre-trade thesis rule. Conviction 5/10 (bounded by

thesis 3's 38%); evidence HIGH on the vehicle mechanics (our own 895-day capture study, on file).

Thesis registry: cio_agent/knowledge/position_theses.json · Full documents: knowledge/deep_dives/ · Not investment advice